Oncotarget: PD-1/PD-L1 expression in anal squamous intraepithelial lesions
(Impact Journals LLC) Dr. Margot Bucau from The H ô pital Bichat-Claude Bernard said, " Anal intraepithelial neoplasia (AIN) is the precursor lesion for anal squamous cell carcinomas (ASCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2021 Category: International Medicine & Public Health Source Type: news

Proteogenomics offers insight to treating head and neck squamous cell carcinoma
(Baylor College of Medicine) A new study identifies three molecular subtypes in head and neck squamous cell carcinoma (HNSCC) that could be used to better determine appropriate treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 7, 2021 Category: International Medicine & Public Health Source Type: news

Researchers aim AI at rising oral cancers with $3.3M grant from National Cancer Institute
(Case Western Reserve University) Researchers at Case Western Reserve University and partners in the United States and India are applying artificial intelligence (AI) to help physicians customize treatments for patients with the most common oral cancer, known as squamous cell carcinomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 5, 2021 Category: Cancer & Oncology Source Type: news

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
SAN MATEO, Calif., Dec. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 ... Biopharmaceuticals, Oncology Rakuten Medical, photoimmunotherapy, Illuminox (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 23, 2020 Category: Pharmaceuticals Source Type: news

Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RARITAN, N.J., December 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. The application marks the first-ever regulatory submission for the treatment of patients with NSCLC with EGFR exon 20 insertion mutations.[1] The Company...
Source: Johnson and Johnson - December 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Scientists regenerate skin with stem cells to see how DNA defects in kids cause cancer
(Cincinnati Children's Hospital Medical Center) Physicians and scientists at Cincinnati Children's Hospital Medical Center used new stem cell technology to regenerate and study living patient-specific skin in the lab, giving them a precise close up view of how inherited DNA defects cause skin damage and deadly squamous cell carcinoma in children and young adults with Fanconi anemia (FA). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 23, 2020 Category: Cancer & Oncology Source Type: news

First-ever phase 3 clinical trial opens for patients with advanced anal cancer
(ECOG-ACRIN Cancer Research Group) A new clinical trial for metastatic anal cancer will determine if a drug that uses the immune system to fight cancer will prolong progression-free survival when given with standard chemotherapy. Study EA2176 will enroll 205 patients in the US with inoperable advanced (spread to other parts of the body) squamous cell anal cancer. Eligibility includes newly diagnosed patients who have not yet started treatment and patients whose cancer has returned/worsened following surgery or radiation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 16, 2020 Category: Cancer & Oncology Source Type: news

Icotinib Plus Radiotherapy Ups Survival in Elderly With Esophageal Cancer Icotinib Plus Radiotherapy Ups Survival in Elderly With Esophageal Cancer
Icotinib with concurrent radiotherapy (RT) boosts survival and may have other benefits compared to RT alone in elderly patients with unresectable esophageal squamous cell carcinoma, according to Chinese researchers.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - October 19, 2020 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Can Squamous Cell Carcinoma Spread to Lymph Nodes?
Title: Can Squamous Cell Carcinoma Spread to Lymph Nodes?Category: Diseases and ConditionsCreated: 10/15/2020 12:00:00 AMLast Editorial Review: 10/15/2020 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - October 15, 2020 Category: Dermatology Source Type: news

Black lives also matter in cancer care
(University of Colorado Anschutz Medical Campus) It is not biology, but access to health care that is causing Black Non-Hispanic patients with squamous cell cancer of the head and neck to have lower survival rates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 1, 2020 Category: Cancer & Oncology Source Type: news

New vulnerability found in lung squamous cancer may facilitate drug targeting
(UNC Lineberger Comprehensive Cancer Center) New cancer research by scientists at UNC Lineberger Comprehensive Cancer Center, and colleagues, shows the potential for targeting a specific circular RNA, known as CDR1as, to attack lung squamous cell cancer. Lung squamous cell cancers comprise up to 30% of all lung cancers and are responsible for about 70,000 new cases and approximately 40,000 deaths each year in the U.S. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 25, 2020 Category: Cancer & Oncology Source Type: news

New First-Line Standard of Care for Esophageal Cancer? New First-Line Standard of Care for Esophageal Cancer?
Pembrolizumab plus chemotherapy should be a new standard of care for first-line treatment, say researchers. Patients with squamous cell carcinomas and higher levels of PD-L1 benefited most.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 23, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

A Breath Test to Diagnose Head and Neck Cancer A Breath Test to Diagnose Head and Neck Cancer
Breath analysis for non-invasive diagnosis of early-stage head and neck squamous cell carcinoma appears to be practical and accurate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

What Are Systemic Disease Causes of Oral Ulcers?
Discussion Oral ulcers are common problems seen by dentists but pediatricians also see them. Usually families have are concerned because they are painful and acute. Ulcers are sometime noticed by the physician and not the family as in the case of herpangina or hand-foot and mouth disease. Chronic or recurrent ulcerations present less commonly and therefore it may be more difficult to determine their etiology. Many of the systemic disease causes of oral ulcers are overall infrequent and/or not common in the pediatric age range. Ulcers can be classified in several ways but acute ulcers are usually painful and last less tha...
Source: PediatricEducation.org - September 21, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Robotic surgery may improve outcomes in mouth and throat cancer
(Cedars-Sinai Medical Center) Robotic surgery for patients with early stage, oropharyngeal squamous cell cancer is associated with improved health outcomes, including better long-term survival, according to a Cedars-Sinai study published Thursday in JAMA Oncology. Oropharyngeal cancer occurs in the back of the throat and includes the base of the tongue and tonsils. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 20, 2020 Category: Cancer & Oncology Source Type: news

Researchers ID new target in drive to improve immunotherapy for cancer
FINDINGSResearchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry  have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.A study in mice found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor that targets the protein BMI1, successfully stopped the growth and spread of the cancer, prevented reoccurrences and eliminated cancer stem cells. This is the first preclinical study to provide evidence that targeting BMI1 proteins enhances immunotherapy and eliminate...
Source: UCLA Newsroom: Health Sciences - July 21, 2020 Category: Universities & Medical Training Source Type: news

Researchers ID new target in drive to improve immunotherapy for cancer
(University of California - Los Angeles Health Sciences) UCLA researchers have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2020 Category: Cancer & Oncology Source Type: news

Tumor-initiating cells establish an IL-33-TGF-{beta} niche signaling loop to promote cancer progression
Targeting the cross-talk between tumor-initiating cells (TICs) and the niche microenvironment is an attractive avenue for cancer therapy. We show here, using a mouse model of squamous cell carcinoma, that TICs play a crucial role in creating a niche microenvironment that is required for tumor progression and drug resistance. Antioxidant activity in TICs, mediated by the transcription factor NRF2, facilitates the release of a nuclear cytokine, interleukin-33 (IL-33). This cytokine promotes differentiation of macrophages that express the high-affinity immunoglobulin E receptor FcRIα and are in close proximity to TICs. ...
Source: ScienceNOW - July 15, 2020 Category: Science Authors: Taniguchi, S., Elhance, A., Van Duzer, A., Kumar, S., Leitenberger, J. J., Oshimori, N. Tags: Cell Biology, Medicine, Diseases, Online Only r-articles Source Type: news

Oncotarget: Tumor markers for carcinoma identified by imaging mass spectrometry
(Impact Journals LLC) Volume 11, Issue 28 of Oncotarget features 'Lipid and protein tumor markers for head and neck squamous cell carcinoma identified by imaging mass spectrometry' by Schmidt et, al. which reported that the authors used MALDI imaging mass spectrometry and immunohistochemistry to seek tumor-specific expression of proteins and lipids in HNSCC samples. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 14, 2020 Category: International Medicine & Public Health Source Type: news

A 3D biofabricated cutaneous squamous cell carcinoma tissue model
(Impact Journals LLC) The cover for issue 27 of Oncotarget features Figure 4, " (A) Bimodal imaging examples of control and treated tumors (red) before and after the treatment period, " by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2020 Category: Cancer & Oncology Source Type: news

Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm
Basel, June 26, 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible and have the potential to aid diagnosis and, ultimately, targeted treatment options for patients. Validated on the VENTANA PD-L1 (SP263) Assay, the algorithm is ready-to-use and integrated within the Roche uPath enterprise software, a universal digital platform for case management, collabo...
Source: Roche Media News - June 26, 2020 Category: Pharmaceuticals Source Type: news

Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm
             Basel, June 26, 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible and have the potential to aid diagnosis and, ultimately, targeted treatment options for patients. Validated on the VENTANA PD-L1 (SP263) Assay, the algorithm is ready-to-use and integrated within the Roche uPath ...
Source: Roche Investor Update - June 26, 2020 Category: Pharmaceuticals Source Type: news

FDA approves pembrolizumab for cutaneous squamous cell carcinoma
Hematology /Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 24, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 24, 2020 Category: Drugs & Pharmacology Source Type: news

Oncotarget: Bacteriome and mycobiome and bacteriome-mycobiome interactions
(Impact Journals LLC) Volume 11 Issue 25 of @Oncotarget reported that the authors aimed to characterize the bacteriome, mycobiome, and mycobiome-bacteriome interactions of oral wash in Head and neck squamous cell carcinoma, or HNSCC, patients and to determine if they are distinct from those of the oral wash of matched non-Head and neck squamous cell carcinoma patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 23, 2020 Category: Cancer & Oncology Source Type: news

Aspergillosis in the Presence of Squamous Cell Carcinoma
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 21, 2020 Category: Respiratory Medicine Authors: MeganB Source Type: news

FDA approves nivolumab for esophageal squamous cell carcinoma
Hematology / Oncology News (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy
PRINCETON, N.J.--(BUSINESS WIRE) June 10, 2020 Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with unresectable advanced, recurrent... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 10, 2020 Category: Drugs & Pharmacology Source Type: news

SARS-CoV-2 Detected in Tongue Squamous Cell Carcinoma Surgical Specimen SARS-CoV-2 Detected in Tongue Squamous Cell Carcinoma Surgical Specimen
SARS-CoV-2 was detected in tissue specimens from a surgically resected tongue squamous cell carcinoma of a patient who later developed COVID-19, according to a case report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - May 26, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Many Patients with Anal Cancer Experienced Chemoradiation Therapy Interruption and Noncompletion
A recent study published in JAMA Oncology revealed that quality improvement initiatives are necessary to optimize treatment and lessen chemotherapy interruption and noncompletion rates among patients with squamous cell anal carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 4, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Erratum for the Research Article: "Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis" by X. Ding, H. Pan, J. Li, Q. Zhong, X. Chen, S. M. Dry, C.-Y. Wang
(Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - April 20, 2020 Category: Science Tags: STKE Errata Source Type: news

How Mohs surgery is used to fight skin cancer: Mayo Clinic Radio Health Minute
Mohs surgery is used to treat the most common skin cancers, basal cell carcinoma and squamous cell carcinoma, as well as some kinds of melanoma. It's especially useful for skin cancers located in areas where it's important to preserve as much healthy skin as possible, such as around the eyes, ears, nose and mouth.  In [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 8, 2020 Category: Databases & Libraries Source Type: news

Moffitt identifies novel therapeutic targets in cutaneous squamous cell carcinoma
(H. Lee Moffitt Cancer Center& Research Institute) Researchers at Moffitt Cancer Center want to devise better therapeutic strategies for patients with cutaneous squamous cell carcinoma (cuSCC) by improving their understanding of how the disease develops. In a new article published online ahead of print in the journal Cancer Research, Moffitt scientists report on their identification of potential therapeutic targets for cuSCC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news

April's SLAS Discovery now available
(SLAS (Society for Laboratory Automation and Screening)) 'Maximizing the Value of Cancer Drug Screening in Multicellular Tumor Spheroid Cultures: A Case Study in Five Head and Neck Squamous Cell Carcinoma Cell Lines' Leads April's SLAS Discovery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 23, 2020 Category: Cancer & Oncology Source Type: news

An Update on Systemic Therapy for Penile Cancer An Update on Systemic Therapy for Penile Cancer
Learn about the most recent advancements in systemic therapy for penile squamous cell carcinoma.Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 17, 2020 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Race, Insurance Status Linked to Lower Cancer Survival
MONDAY, March 16, 2020 -- Nonwhite, uninsured patients with clinically favorable human papillomavirus (HPV)-associated squamous cell carcinoma of the head and neck (SCCHN) have higher mortality than their white peers, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 16, 2020 Category: Pharmaceuticals Source Type: news

Rare driver mutations disrupt NOTCH signaling to promote squamous cell carcinoma
(American Association for the Advancement of Science) Head and neck squamous cell carcinoma (HNSCC) -- a group of cancers that affect the the mouth, nose and throat -- is a disease driven by mutations in the NOTCH tumor suppressor signaling pathway, according to a new study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2020 Category: Cancer & Oncology Source Type: news

Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling
In most human cancers, only a few genes are mutated at high frequencies; most are mutated at low frequencies. The functional consequences of these recurrent but infrequent "long tail" mutations are often unknown. We focused on 484 long tail genes in head and neck squamous cell carcinoma (HNSCC) and used in vivo CRISPR to screen for genes that, upon mutation, trigger tumor development in mice. Of the 15 tumor-suppressor genes identified, ADAM10 and AJUBA suppressed HNSCC in a haploinsufficient manner by promoting NOTCH receptor signaling. ADAM10 and AJUBA mutations or monoallelic loss occur in 28% of human HNSCC c...
Source: ScienceNOW - March 11, 2020 Category: Science Authors: Loganathan, S. K., Schleicher, K., Malik, A., Quevedo, R., Langille, E., Teng, K., Oh, R. H., Rathod, B., Tsai, R., Samavarchi-Tehrani, P., Pugh, T. J., Gingras, A.-C., Schramek, D. Tags: Genetics, Medicine, Diseases reports Source Type: news

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer
RARITAN, NJ, March 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. JNJ-6372 is an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications.[1...
Source: Johnson and Johnson - March 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Tracking down false parkers in cancer cells
(University of W ü rzburg) In squamous cell carcinoma, a protein ensures that unneeded proteins are no longer disposed of. A research team at the University of W ü rzburg has switched off this protein for the first time. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 10, 2020 Category: Cancer & Oncology Source Type: news

Radiation/immunotherapy combo shows promise for recurrent/metastatic head and neck cancers
(American Society for Radiation Oncology) A new phase II trial finds that a combination of radiation therapy and immunotherapy led to encouraging survival outcomes and acceptable toxicity for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). The combination of radiation and pembrolizumab may offer a new treatment option for patients who are ineligible for cisplatin chemotherapy, part of standard treatment for the disease. Findings will be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2020 Category: Cancer & Oncology Source Type: news

FDA D.I.S.C.O.: FDA approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma
FDA medical oncologists discuss the September 28, 2018, approval of cemiplimab-rwlc for the treatment of select patients with cutaneous squamous cell carcinoma. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

IU researcher makes skin cancer discovery
(Indiana University School of Medicine) An Indiana University cancer researcher has identified eight new genomic regions that increase a person's risk for skin cancer. Jiali Han, Ph.D., and colleagues discovered eight new loci--locations on a person's genome--that are susceptible to the development of squamous cell skin cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 18, 2020 Category: Cancer & Oncology Source Type: news

FDA Grants 2 Fast Track Designations for ALX148
The FDA granted 2 Fast Track designations for ALX148 for the first-line treatment of patients with head and neck squamous cell carcinoma, and for the second-line treatment of patients with HER2-positive gastric or gastroesophageal junction carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Staging Guidelines May be Missing Biomarkers that Affect Outcomes in OPSCC
Researchers suggested that the 2017 classifications do not currently allow for uniform stratification and proper outcome prognostication for surgically treated patients with p16-positive oropharyngeal squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 17, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Gaps in cure rate appear linked to race and insurance status for common HPV-related cancer
(National Comprehensive Cancer Network) Largest population-based analysis to date on outcomes for HPV-positive oropharyngeal squamous cell carcinoma of the head and neck (SCCHN) finds significant racial and socioeconomic disparities, according to new research in JNCCN-Journal of the National Comprehensive Cancer Network. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 6, 2020 Category: Cancer & Oncology Source Type: news

UArizona receives $6.9m grant to study prevention of non-melanoma skin cancer
(University of Arizona Health Sciences) Skin cancer is the most common malignancy worldwide, and one in three new cancers diagnosed is a form of skin cancer. In response, a team of researchers at the University of Arizona Cancer Center is developing new strategies to prevent and reduce the risk of squamous cell carcinoma, the second most-common form of non-melanoma skin cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2020 Category: Cancer & Oncology Source Type: news

Clostridium perfringens enterotoxin induces claudin-4 to activate YAP in oral squamous cell
(Impact Journals LLC) Oncotarget Volume 11, Issue 4: Treatment of human oral squamous cell carcinoma cell lines HSC3 and HSC4 with Clostridium perfringens enterotoxin, induced CLDN4 nuclear translocation to enhance epithelial-mesenchymal transition, stemness, cell proliferation, and invasive ability. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 4, 2020 Category: Cancer & Oncology Source Type: news

Scientists find RNA affecting skin cancer progression
(University of Turku) Researchers at the University of Turku, Turku University Central Hospital, and Western Cancer Center (FICAN West) have discovered a new RNA molecule, PRECSIT, which regulates the growth and invasion of squamous cell carcinoma of the skin. In the future, PRECSIT could potentially serve as a new marker for the detection of rapidly advancing or spreading squamous cell carcinoma and as a target for new therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 4, 2020 Category: Cancer & Oncology Source Type: news

The virome of HPV-positive tonsil squamous cell carcinoma and neck metastasis
(Impact Journals LLC) In this prospective study, a pan-pathogen microarray was used to determine the virome of early stage, p16-positive OPSCC and neck metastasis treated with transoral robotic surgery and neck dissection. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 27, 2020 Category: Cancer & Oncology Source Type: news